Clinical trials
Schizophrenia clinical trials
Below are recruiting schizophrenia clinical trials, each written for real people, not researchers. We’re tracking 317 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07703670Recruiting
MicroRNA markers in first episode schizophrenia
This study looks at tiny molecules called microRNAs in the blood of people having their first episode of schizophrenia. It aims to find markers that could help guide treatment choices.
Glen Oaks, New YorkAges 15–40 - NCT04033679Recruiting
Brain stimulation to help people stay on schizophrenia medications
This study tests whether a non-invasive brain stimulation treatment can improve medication adherence in people with schizophrenia or schizoaffective disorder. If it helps you take meds more reliably, it may also support more stable mental health over time.
Toronto, OntarioAges 18 years+ - NCT04113993RecruitingPhase 4
Bazedoxifene study in women with schizophrenia
This trial tests whether bazedoxifene can help women with schizophrenia who are stable on their current medicines. You may be asked to do questionnaires and thinking (cognitive) tests to see if symptoms or brain-related measures change.
Melbourne, VictoriaAges 18–65 - NCT04159662Recruiting
Brain scans to study thinking in schizophrenia and depression
This study uses brain imaging to better understand how thinking works in people with schizophrenia or major depression. Your results may help researchers learn what brain patterns match different thinking and symptoms.
Ottawa, OntarioAges 18–60 - NCT04226898RecruitingPhase 2
Synbiotic supplement to lessen schizophrenia symptoms
This Phase 2 trial tests whether a “synbiotic” supplement (a mix of probiotics and prebiotics) can reduce symptoms of schizophrenia or schizoaffective disorder. It may help by targeting gut-related immune and inflammation pathways that could affect brain symptoms.
Batlimore, MarylandAges 18–65 - NCT04267003Recruiting
Brain stimulation study for thinking and brain chemistry in schizophrenia
This study tests whether a brain stimulation approach can improve thinking (cognition) in people with schizophrenia and how it changes brain electrical signals and a brain chemical called GABA. It may help researchers understand new ways to support thinking and symptoms.
Sacramento, CaliforniaAges 18–47 - NCT04432116Recruiting
Virtual reality training for schizophrenia and bipolar symptoms
This study looks at whether virtual reality and time-based training can improve symptoms for people with schizophrenia or bipolar disorder. You may do virtual-reality tasks as part of your care plan while the team tracks changes over time.
StrasbourgAges 18–60 - NCT04629352Recruiting
tDCS brain-stimulation for hearing voices in schizophrenia
This study tests whether a non-invasive brain-stimulation treatment (tDCS) can improve response to care in people who experience clinically significant hearing voices. It may help by changing brain activity, aiming to reduce or improve auditory hallucinations.
Bengaluru, KarnatakaAges 18–45 - NCT04655235Recruiting
Study brain chemical systems in people with schizophrenia
This study looks at brain chemicals involved in “glutamate” and “GABA” signaling in people with schizophrenia (and separately in healthy volunteers). It may help researchers understand what’s going wrong in the brain and guide future treatments.
Aachen, Northrine-WestphaliaAges 18–80 - NCT04745143RecruitingPhase 2
NMDA-enhancer medicine tested for schizophrenia without antipsychotics
This Phase 2 trial tests a single medicine intended to help people with schizophrenia who cannot take standard antipsychotic medications due to side effects or poor response. It may help reduce schizophrenia symptoms, but whether you can join depends on your diagnosis, medication history, and health conditions.
TaichungAges 18–65 - NCT04807530Recruiting
MRI brain study for people with schizophrenia symptoms
This study uses brain scans to look at how a specific brain area works in schizophrenia. If you qualify, it may help researchers better understand the brain changes linked to symptoms.
San Francisco, CaliforniaAges 18–64 - NCT04871048Recruiting
tDCS training to reduce cannabis use in people with schizophrenia
This trial tests whether a non-painful brain stimulation method (tDCS) can help people with schizophrenia who also have moderate-to-severe cannabis use disorder reduce or quit cannabis. It also involves MRI scanning to help study brain changes.
BronAges 18–60 - NCT04917302RecruitingPhase 2
NMDA and anti-inflammatory add-on for treatment-resistant schizophrenia
This trial tests whether combining an NMDA “signal-supporting” treatment with an anti-inflammatory medicine can reduce symptoms in people with schizophrenia who don’t respond well to usual antipsychotic drugs. If you’ve tried at least two antipsychotics and you’re still symptomatic, this study may be worth screening for.
TaichungAges 18–65 - NCT04959201RecruitingPhase 2
NMDA and antioxidant add-on to treat schizophrenia symptoms
This Phase 2 trial tests whether adding an “NMDA-enhancing” treatment plus an antioxidant can improve ongoing schizophrenia symptoms over 12 weeks. It’s meant for people who still have symptoms even though their usual antipsychotic dose has been stable for at least 3 months.
TaichungAges 18–65 - NCT05025605RecruitingPhase 1
Study medicine for agitation in youth with bipolar or schizophrenia
This Phase 1 trial tests whether BXCL501 is safe and can help reduce agitation in children and teens who have bipolar disorder or schizophrenia. You may be considered if your agitation is significant during screening, but certain recent medication and health factors can make you ineligible.
Anaheim, CaliforniaAges 10–17 - NCT05052853RecruitingPhase 2
Early treatment trial for early schizophrenia warning signs
This Phase 2 study tests an NMDA-enhancer medicine to see if it can help people who are in the early “prodromal” stage—when symptoms are starting but full schizophrenia is not diagnosed yet. It aims to reduce or prevent worsening symptoms over the study period.
TaichungAges 13–45 - NCT05074732Recruiting
Study of forensic mental health admissions after a service move
This study looks at all adult admissions to Ireland’s National Forensic Mental Health Service during a specific time window. It may help improve how the new forensic service at Portrane runs in the future.
DublinAges 18 years+ - NCT05159349Recruiting
Studying mental health support for adults with schizophrenia
This trial is studying mental health across the daily life of people living in the community who have schizophrenia. It may help by improving how care is planned and supported over time for people living in Shanghai.
ShanghaiAges 18–65 - NCT05184335RecruitingPhase 3
Brilaroxazine for adults with schizophrenia
This study tests whether brilaroxazine works and is safe for people with schizophrenia. It mainly aims to help people whose symptoms are still present despite prior treatment, while excluding those with certain other diagnoses or substance/drug issues.
Phoenix, ArizonaAges 18–65 - NCT05208190RecruitingPhase 4
Clozapine to prevent violence in schizophrenia
This trial tests whether clozapine can reduce repeat violent behavior in people with schizophrenia or schizoaffective disorder. Participants are randomly assigned to clozapine or usual care to see which approach works better for preventing violence.
Los Angeles, CaliforniaAges 18–65 - NCT05240976RecruitingPhase 2
Testing add-on treatments for very treatment-resistant schizophrenia
This trial tests a combination of an NMDA-targeting medicine and an anti-inflammatory treatment for people with schizophrenia that has not responded well to several standard treatments, including clozapine. If you qualify, the goal is to see whether this combination improves symptoms more than usual care.
TaichungAges 18–65 - NCT05276050Recruiting
Brain-circuit treatment to help people with schizophrenia quit smoking
This study tests a circuitry-guided approach to help people with schizophrenia quit smoking. It may help reduce cravings and improve quitting, while also watching for safety issues.
Houston, TexasAges 22–65 - NCT05296720Recruiting
EEG study of touch prediction in people with schizophrenia
This study uses a special brain test (EEG) while you do a touch-related task to see how your brain predicts what comes next. It may help researchers understand brain and behavior differences in schizophrenia and how sensory processing works.
StrasbourgAges 18–60 - NCT05303064RecruitingPhase 3
Study of weight gain medicine for teens with certain mood or psychosis
This Phase 3 study tests a treatment aimed at reducing unhealthy weight gain in teens with schizophrenia or bipolar I disorder, using changes in BMI (a height-and-weight measure). It may help families who are concerned about weight changes that can happen with some psychiatric medicines.
Dothan, AlabamaAges 10–17
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for schizophrenia?
- Yes. Clin2 currently lists 317 recruiting schizophrenia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a schizophrenia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a schizophrenia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.